Related Topics
     

    Dyer: News Releases & Feature Stories

     
    04/03/2014
    Tumor suppressor gene TP53 mutated in 90 percent of most common childhood bone tumor

    St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project finds TP53 gene is altered in nearly all osteosarcomas; results help explain how tumors withstand radiation therapy. (Michael Dyer, PhD, and Jinghui Zhang, PhD)

     
     
    12/09/2013
    Stressing cancer out

    Even cancer cells can feel stress. In fact, it can kill them. According to new research led by St. Jude Children’s Research Hospital, drugs that enhance a process called oxidative stress may offer a new way to combat an aggressive soft tissue tumor called rhabdomyosarcoma.

     
     
    12/09/2013
    Gene sequencing project finds family of drugs with promise for treating childhood tumor

    St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project study identifies drugs that enhance oxidative stress as possible weapon against most common pediatric soft tissue tumor. (Dr. Michael Dyer)

     
     
    05/29/2013
    James Hoffman, Pharm.D., named American Society of Health-System Pharmacists fellow

    James M. Hoffman, Pharm.D., medication outcomes and safety officer at St. Jude Children’s Research Hospital, has been named a fellow by the American Society of Health-System Pharmacists (ASHP) for excellence in pharmacy practice.

     
     
    05/09/2013
    St. Jude scientist named Howard Hughes Medical Institute investigator

    Michael Dyer, Ph.D., of St. Jude Children's Research Hospital, has been recognized as one of the nation’s leading biomedical researchers by the Howard Hughes Medical Institute.

     
     
    07/09/2012
    Revealing the Secrets of the Genome

    Pediatric Cancer Genome Project scientists begin to uncover treasures.

     
     
    03/13/2012
    Genome sequencing initiative links altered gene to age-related neuroblastoma risk

    St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project and Memorial Sloan-Kettering Cancer Center discover first gene alteration associated with patient age and neuroblastoma outcome. (Dr. Michael Dyer)

     
     
    01/11/2012
    Gene identified as a new target for treatment of aggressive childhood eye tumor

    St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project findings help solve mystery of retinoblastoma’s rapid growth in work that also yields a new treatment target and possible therapy. (Dr. Michael Dyer)

     
     
    08/15/2011
    Childhood eye tumor made up of hybrid cells with jumbled development

    St. Jude Children’s Research Hospital scientists lead research that settles a century-old debate about retinoblastoma’s beginnings and identify new targets for treating the childhood eye tumor

     
     
    03/29/2010
    Advances reported in quest for drugs targeting childhood cancer

    Investigators believe they have identified the founding member of a chemical family they hope will lead to a new class of cancer drugs, the first designed specifically against a childhood tumor, according to research led by St. Jude Children’s Research Hospital scientists.

     
     
    07/13/2009
    Relishing the view

    The wait is over for scientists at St. Jude who envisioned the day when technology would transform the way they analyze DNA samples. Using new technology that churns out massive amounts of data, investigators now have a comprehensive view of genomes to increase their understanding of cancers and infectious diseases.

     
     
    06/05/2009
    Scientists discover new insight into primate eye evolution

    Researchers comparing the fetal development of the eye of the owl monkey with that of the capuchin monkey have found that only a minor difference in the timing of cell proliferation can explain the multiple anatomical differences in the two kinds of eyes.

     
     
    04/09/2009
    Eye cells believed to be retinal stem cells are misidentified

    Cells isolated from the eye that many scientists believed were retinal stem cells are, in fact, normal adult cells, investigators at St. Jude have found. If retinal stem cells could be obtained, they might provide the basis for treatments to restore sight to millions of people with blindness caused by retinal degeneration.

     
     
    03/26/2009
    St. Jude researcher named Howard Hughes Early Career Scientist

    Michael Dyer, a faculty member at St. Jude Children's Research Hospital, has been tapped as one of the nation’s leading scientists by the Howard Hughes Medical Institute.

     
     
    05/05/2008
    A closer look

    An electron microscope uses a beam of electrons to produce highly detailed images that reveal a specimen’s structure and composition. The new instrument, one of only 200 of its type in the world, is the centerpiece of a recent expansion of cellular imaging at St. Jude.

     
     
    04/07/2008
    Turning scientific beliefs upside-down

    St. Jude investigators disprove a century-old theory, turning established scientific beliefs on their heads. This exciting discovery may someday have applications for such diseases as Alzheimer’s and Parkinson’s.

     
     
    10/19/2007
    St. Jude identifies the specific cell that causes eye cancer

    Researchers found that certain mutations enable specific cells in the retina to multiply and cause eye cancer, a finding that suggests deliberate genetic manipulations might coax an injured brain to repair itself.

     
     
    05/25/2007
    Study challenges conventional wisdom about cancer cells

    A team of St. Jude investigators challenged conventional wisdom about the eye cancer retinoblastoma by using a mouse model that allowed them to study the tumors as they develop and grow.

     
     
    11/02/2006
    St. Jude announces breakthrough in eye cancer treatment

    St. Jude scientists have demonstrated in the laboratory a new treatment for retinoblastoma that reduces the size of the tumor without causing the side effects common with standard chemotherapy.

     
     
    06/06/2006
    Genetic insights may explain retinal growth, eye cancer

    Investigators at St. Jude have discovered the role of several key genes in the development of the retina, and in the process have taken a significant step toward understanding how to prevent or cure the potentially deadly eye eye cancer retinoblastoma.

     
     
    11/14/2005
    Lab model used to improve eye cancer therapy

    Investigators at St. Jude have demonstrated in laboratory studies a potential new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy.

     
     
    12/14/2004
    New model of rare childhood blindness holds promise for testing preventive therapies

    The development of a laboratory model for a rare, inherited form of blindness holds promise that scientists might one day be able to test new treatments to prevent or cure this devastating disease of the retina.

     
     
    06/22/2004
    Dyer named 2004 Pew Scholar

    Michael Dyer, PhD, an assistant member of Developmental Neurobiology, has been named a 2004 Pew Scholar.

     
     
    06/07/2004
    New laboratory model can be used to test new treatments for pediatric eye cancer

    The development of a mouse model that closely mimics the human eye cancer retinoblastoma, gives investigators a way to test new therapies for this disease in the laboratory for the first time.

     
     
    04/22/2004
    Retinoblastoma Research: Bench to Bedside

    Children with retinoblastoma reap the benefits of basic laboratory research while St. Jude researchers harness technology and knowledge to give clinicians a vast array of treatment options.